Yang Sai
Impact in
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 6
- Oncology 14
- Co-authors
- Kristopher W. Krausz (5 shared papers)Frank J. Gonzalez (5 shared papers)Yi Gu (7 shared papers)Magang Shou (2 shared papers)Tian J. Yang (2 shared papers)Harry V. Gelboin (2 shared papers)Kai Yang (5 shared papers)Yanxiang Zhang (5 shared papers)
- Journals
- Cancer Research (4 papers)Journal of Medicinal Chemistry (3 papers)European Journal of Pharmaceutical Sciences (2 papers)Clinical Therapeutics (2 papers)ACS Nano (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Yang Sai
43 papers receiving 984 citations
Peers
Comparison fields: 5 of 102
- Pharmacology 297
- Oncology 280
- Hepatology 77
- Biotechnology 60
- Biochemistry 50
Countries citing papers authored by Yang Sai
This map shows the geographic impact of Yang Sai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yang Sai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yang Sai more than expected).
Fields of papers citing papers by Yang Sai
This network shows the impact of papers produced by Yang Sai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yang Sai. The network helps show where Yang Sai may publish in the future.
Co-authors
The 25 scholars most cited alongside Yang Sai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 123 | |
| 2 | 2009 | 111 | |
| 3 | 2014 | 111 | |
| 4 | 2019 | 69 | |
| 5 | 2022 | 56 | |
| 6 | 1999 | 48 | |
| 7 | 2022 | 42 | |
| 8 | 2017 | 42 | |
| 9 | 2019 | 41 | |
| 10 | 2014 | 40 | |
| 11 | 2023 | 37 | |
| 12 | 2000 | 36 | |
| 13 | 2022 | 27 | |
| 14 | 1998 | 22 | |
| 15 | 2021 | 20 | |
| 16 | An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. | 1999 | 20 |
| 17 | 2007 | 17 | |
| 18 | 2023 | 16 | |
| 19 | 2019 | 16 | |
| 20 | 2013 | 15 |
About Yang Sai
Yang Sai is a scholar working on Molecular Biology, Oncology, Pharmacology, Pulmonary and Respiratory Medicine and Hepatology, having authored 44 papers that have together received 1.0k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (11 papers), Lung Cancer Treatments and Mutations (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Liver physiology and pathology (5 papers), Chronic Myeloid Leukemia Treatments (5 papers), Nanoplatforms for cancer theranostics (4 papers), Analytical Chemistry and Chromatography (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Pharmacology (297 citations), Oncology (280 citations), Hepatology (77 citations), Biotechnology (60 citations) and Biochemistry (50 citations). Yang Sai has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Kristopher W. Krausz, Frank J. Gonzalez, Yi Gu, Magang Shou, Tian J. Yang, Harry V. Gelboin, Kai Yang, Yanxiang Zhang, Pei Pei and Harry V. Gelboin. Their work appears in journals such as Cancer Research, Journal of Medicinal Chemistry, European Journal of Pharmaceutical Sciences, Clinical Therapeutics and ACS Nano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.